NCT06827860 2025-12-18
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
Clinical Trials
7 trialsNCT03734198 2025-11-26
IDA53
French Innovative Leukemia Organisation
Phase 2 Active not recruiting
NCT04176718 2025-10-07
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Massachusetts General Hospital
Phase 2 Recruiting
NCT03836014 2024-12-06
CONFIRM
Assistance Publique - Hôpitaux de Paris
Phase 3 Active not recruiting
NCT03450057 2024-03-29
DARE
Hellenic Society of Hematology
Phase 2 Completed
NCT03679624 2023-10-23
Daratumumab Plus Ibrutinib in Patients With WaldenstrÓ§m's Macroglobulinemia
Weill Medical College of Cornell University
Phase 2 Terminated
NCT03143036 2018-06-07
Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma
National University Hospital, Singapore
Phase 2 Unknown